Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant

Ottawa Hospital Research Institute

$692,730.00

Differential role of myogenic regulatory factors in establishing muscle-specific gene expression

EF 2009-10

Résumé
Myogenin is a regulator of gene expression that is critically required for muscle formation. However, the mechanism by which this important protein mediates its role in muscle development is not well established. Using technologies that allow us to determine the other cellular proteins that specifically associate with myogenin, our work will determine how this critical factor decides which genes to turn on in muscle cells. The knowledge gained from these studies of myogenin function will facilitate the development of novel therapies to treat muscular dystrophy.
Programme
Operating Grant
Emplacement
Ontario, Canada
Type de bénéficiaire
Other
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
200789
Name
Dilworth Jeffrey J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Biochemistry & Molecular Biology - B
Projecttitle
Differential role of myogenic regulatory factors in establishing muscle-specific gene expression
Programtype2
Operating Grants
Orgnameinp2
Ottawa Hospital Research Institute
Cihramount2
$692,730
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Coactivators; Gene Expression; In Vitro Transcription; Muscle Differentiation; Proteomics; Transcription Factor
Abstract
Myogenin is a regulator of gene expression that is critically required for muscle formation. However, the mechanism by which this important protein mediates its role in muscle development is not well established. Using technologies that allow us to determine the other cellular proteins that specifically associate with myogenin, our work will determine how this critical factor decides which genes to turn on in muscle cells. The knowledge gained from these studies of myogenin function will facilitate the development of novel therapies to treat muscular dystrophy.
Competitiondate
201003
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Dilworth, Jeffrey J
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $692,730~ $0~